RhoDx Latest News

Stay up to date on our progress towards better methods for cancer screening and monitoring.

ST. LOUIS, November 11, 2021 – RhoDx, Inc. today announced the appointment of Todd Druley, MD, PhD as an advisor to guide clinical development of the company’s technology portfolio. Dr. Druley was Chief Medical Officer of ArcherDx prior to their acquisition by Invitae in October of 2020. He is an Associate Professor of pediatric hematology and oncology, developmental biology and genetics at Washington University School of Medicine in St. Louis, an inductee into the American Society of Clinical Investigators and a scientific advisor for the B+ Foundation and the Eli Seth Matthews Leukemia Foundation. Dr. Druley brings a wealth of expertise in the translational application of cancer genomics that is key to clinical translation of the company’s core technologies which enable earlier cancer detection in more cancer patients through improved cell-free DNA-based liquid biopsy.

“To realize the promise of personalized cancer treatment, we need better cancer diagnostics that are cost effective and highly precise. I’m pleased to advise RhoDx because I believe their technology will provide earlier detection of cancer in many more patients” stated Druley.

“We are thrilled that Dr. Druley has decided to join our team as an advisor” said Charlie Rodi, CEO of RhoDx. “Todd’s wealth of experience in clinical research and his track record of successful development of cancer diagnostics will greatly accelerate the clinical development of RhoDx’ core technologies.”

About RhoDx

RhoDx is a St. Louis-based, privately held company founded to improve cancer screening and save lives. The company’s three core technologies, PointSuppressor™, NexGenAbler™, and MethylMarker™ offer several advantages in cancer detection including orders of magnitude improvements in limit of detection, throughput, and sequencing costs when compared to existing methods. Combined, they enable a highly specific, sensitive, and automation-friendly method for quantitative measurement of the mutations that drive cancer, and the methylations that allow cancer, within the same tube. Our mission is to leverage these technologies to improve liquid biopsy and enable more scalable, sensitive detection of cancer to dramatically decrease cancer deaths through early, descriptive detection of many cancers. We believe better methods for screening and monitoring cancer will have the biggest impact on patient outcomes this decade.

Contact:
Dr. Charlie Rodi
RhoDx, Inc.
(858) 353-1084
rhodx@rhodx.com